Navigation Links
Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress

PARIS, July 9, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) today reported data from its ongoing Phase 2/3 study evaluating the efficacy of OBI-1, an investigational recombinant porcine factor VIII (FVIII), for the treatment of serious bleeds in people with acquired hemophilia A. According to the interim analysis, seven out of seven trial participants receiving OBI-1 experienced control and subsequent resolution of their bleeds. Edward Gomperts, MD, Attending Hematologist and Director of Clinical Research, Clinical Investigation Center at Children's Hospital Los Angeles and Consultant to Inspiration, presented the findings in an oral presentation at the 2012 World Federation of Hemophilia (WFH) World Congress in Paris.

Acquired hemophilia A is a rare, sometimes life-threatening bleeding disorder that is caused by the development of autoantibodies (inhibitors) against FVIII, a key protein contributing to normal coagulation of blood. The antibodies render the native factor VIII ineffective in promoting clotting. Treatment of acquired hemophilia can be challenging, because the antibodies will attack any human form of FVIII. OBI-1 is designed to avoid recognition by antibodies to human FVIII. People with inhibitors to human FVIII may respond to porcine FVIII, replacing the missing step in their coagulation cascade."People with acquired hemophilia currently have limited treatment options to control serious bleeding episodes. These preliminary findings are encouraging and suggest that further investigation of the efficacy and safety of OBI-1 in this population is warranted," said Dr. Gomperts.

A second Accur8 Phase 2/3 clinical trial is also underway to evaluate OBI-1's ability to control bleeding in people with congenital hemophilia A with inhibitors and the safety of this drug in this population.

As part of Inspiration's expanded presence at the WFH World Congress, the company will host a symposium tomorrow entitled, "Hemophilia B: The Neglected Hemophilia," featuring a panel of experts exploring advancements in research, treatment and advocacy for hemophilia B, which is far less prevalent than hemophilia A.

Inspiration has a second product under development, which is a recombinant factor IX therapy being evaluated for the prevention and treatment of bleeding in people with hemophilia B and its safety profile in this population. This product is currently under regulatory review in both the U.S. and the EU.

"We are thrilled to be growing our presence and involvement at the WFH annual congress, the premier global scientific gathering for the hemophilia community," said John P. Butler, Chief Executive Officer of Inspiration. "Our goal as a company centers on broadening treatment choices, expanding global access to therapies and advancing innovation for people with all types of hemophilia. This meeting gives us an opportunity to connect face-to-face with leaders in the global hemophilia community, discuss their ongoing needs and determine the role Inspiration can play in improving the lives of people with hemophilia around the world."  

Study Design and ResultsThe Accur8 Auto-antibody trial is an ongoing prospective, open label, Phase 2/3 study. The primary objective of the study is to evaluate the efficacy of OBI-1 treatment for serious (life- or limb-threatening) bleeds in individuals age 18 and older with acquired hemophilia A, as measured by the control of bleeding 24 hours after initial OBI-1 dose administration.

The interim analysis presented today included data from the first seven trial participants with severe bleeds not controlled with bypassing agents who were enrolled and treated with OBI-1. To date, 15 subjects have been enrolled and completed treatment in the clinical trial. Participants received 200U/kg of OBI-1 on first injection and were subsequently dosed based on target FVIII levels. All seven subjects experienced successful control of bleeds at 24 hours and subsequent resolution of their bleeds. Therapeutic FVIII activity levels were achieved and maintained with intermittent OBI-1 administration based on FVIII levels. Of the adverse events reported during the study thus far five were serious, but these were not considered by investigators to be treatment-related. As part of the ongoing Accur8 Auto-antibody trial, adverse event data continues to be collected including the evaluation of inhibitors to porcine factor VIII.

About Inspiration BiopharmaceuticalsAs the only biopharmaceutical company dedicated solely to hemophilia, Inspiration is committed to improving the care of people with this condition by broadening treatment choices, expanding global access to care and advancing innovative therapies. Founded by two families whose sons have hemophilia, Inspiration is inspired to make a difference in the lives of people impacted by hemophilia around the world.

Inspiration's lead product candidates are OBI-1 and IB1001, an investigational intravenous recombinant factor IX being developed for the treatment of hemophilia B.

For more information about Inspiration Biopharmaceuticals, please visit MediaCompanyKate LewisGordon H. BusenbarkFeinstein Kean HealthcareSenior Vice President, Chief Financial OfficerTel: +1-617-577-8Tel: +1-617-588-1802Email:

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
2. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
4. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
5. 2012 Pharmaceutical Diversification Trends, Egypt & Saudi Arabia Pharmaceutical Markets Analyzed in New Research Reports
6. Herborium Group Reports Record 6 Month Revenues
7. Kewaunee Scientific Reports Significantly Improved Results for Fourth Quarter
8. Sinovac Reports Progress in EV71 Vaccine Phase III Clinical Trial and Commercialization Preparation Status
9. Reports 82% Year-Over-Year Revenue Growth
10. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
11. China Health Resource Reports on Record Year-End 2011 Results Continuing Strong in 2012
Post Your Comments:
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Care Market by Type (Dressings, Therapy Devices, Active Wound ... Out-Patient Facility), and Geography - Global Forecast to 2020" ... --> --> The purpose of this ... of the global advanced wound care market. It involves ...
(Date:11/26/2015)... -- Research and Markets ( ) has ... Horizons and Growth Strategies in the Italian Therapeutic ... Forecasts, Competitive Intelligence, Emerging Opportunities" report to ... --> This new 247-page report provides ... monitoring market, including emerging tests, technologies, instrumentation, sales ...
(Date:11/25/2015)... SYDNEY , Nov. 26, 2015  The total global ... nearly 7% over 2015-2016. Latin America ... Asia , (excluding Japan ), is ... continues to face increased healthcare expenditure. In 2013-2014, ... expenditure declined from 43.5% in 2008-2009 to 41.2% in 2013-2014. ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is a ... X. With ProSidebar: Fasion, video editors can easily add an informative sidebar to ... title opener. Utilize presets featuring self-animating drop zones, lines, bars, and text with ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... failing. Secura Consultants has prided itself for not only fulfilling the needs of ... protection solutions at an affordable price and providing top-tier customer service. However, there's ...
(Date:11/27/2015)... ... November 27, 2015 , ... Avid collector, Andrew Hawley ... Michigan boxing style concert posters. This is one of Joplin's most famous and beautiful ... at the University of Michigan in Ann Arbor. The According to Hawley, "It is ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... Representative. As a franchise owner, Somu now offers travelers, value and care based ... packages, private cruise sales, as well as, cabin upgrades and special amenities such ...
(Date:11/26/2015)... ... November 26, 2015 , ... Pixel Film ... trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes with 30 ... with any font, giving users limitless opportunities to stylize and create designs quickly ...
Breaking Medicine News(10 mins):